DE69633680D1 - Behandlung von zns-wirkungen des hiv mit vx-478, allein oder kombiniert mit azt oder 3tc - Google Patents

Behandlung von zns-wirkungen des hiv mit vx-478, allein oder kombiniert mit azt oder 3tc

Info

Publication number
DE69633680D1
DE69633680D1 DE69633680T DE69633680T DE69633680D1 DE 69633680 D1 DE69633680 D1 DE 69633680D1 DE 69633680 T DE69633680 T DE 69633680T DE 69633680 T DE69633680 T DE 69633680T DE 69633680 D1 DE69633680 D1 DE 69633680D1
Authority
DE
Germany
Prior art keywords
azt
alone
combined
treating hiv
cns effects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69633680T
Other languages
English (en)
Other versions
DE69633680T2 (de
Inventor
Ramsewak Chaturvedi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69633680D1 publication Critical patent/DE69633680D1/de
Publication of DE69633680T2 publication Critical patent/DE69633680T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
DE69633680T 1995-12-05 1996-12-05 Behandlung von zns-wirkungen des hiv mit vx-478, allein oder kombiniert mit azt oder 3tc Expired - Fee Related DE69633680T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/567,199 US5646180A (en) 1995-12-05 1995-12-05 Treatment of the CNS effects of HIV
US567199 1995-12-05
PCT/US1996/019447 WO1997020554A1 (en) 1995-12-05 1996-12-05 Treatment of the cns effects of hiv with vx-478, alone or in combination with azt or 3tc

Publications (2)

Publication Number Publication Date
DE69633680D1 true DE69633680D1 (de) 2004-11-25
DE69633680T2 DE69633680T2 (de) 2006-02-23

Family

ID=24266147

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69633680T Expired - Fee Related DE69633680T2 (de) 1995-12-05 1996-12-05 Behandlung von zns-wirkungen des hiv mit vx-478, allein oder kombiniert mit azt oder 3tc

Country Status (23)

Country Link
US (1) US5646180A (de)
EP (1) EP0866696B1 (de)
JP (1) JP2000501713A (de)
KR (1) KR19990071750A (de)
CN (1) CN1203530A (de)
AP (1) AP864A (de)
AT (1) ATE279922T1 (de)
AU (1) AU722850B2 (de)
BR (1) BR9611861A (de)
CA (1) CA2238471A1 (de)
CZ (1) CZ291994B6 (de)
DE (1) DE69633680T2 (de)
ES (1) ES2231828T3 (de)
HU (1) HUP9903673A3 (de)
NO (1) NO317837B1 (de)
NZ (1) NZ324603A (de)
OA (1) OA10691A (de)
PL (1) PL187747B1 (de)
PT (1) PT866696E (de)
RU (1) RU2203658C2 (de)
UA (1) UA61902C2 (de)
WO (1) WO1997020554A1 (de)
ZA (1) ZA9610139B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
HUP9903249A3 (en) * 1996-06-25 2001-04-28 Glaxo Group Ltd Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
HUP9903098A3 (en) * 1996-06-25 2000-01-28 Glaxo Group Ltd Combination comprising vx478, zidovudine and/or 1592u89 and pharmaceutical composition containing them
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
BR9809124A (pt) * 1997-05-17 2000-08-01 Glaxo Group Ltd Combinação, formulação, farmacêutica, processo para o tratamento de uma infecção por hiv em um animal, infectado, uso de (-)-(1s, 4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-cicl openteno-1-metanol, e, pacote de paciente
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US6576231B2 (en) * 1997-09-12 2003-06-10 Schering Ag Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6309632B1 (en) * 1998-04-28 2001-10-30 Immunex Corporation Methods for treating HIV-infected patients by administering GM-CSF
US6875773B1 (en) * 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
US20090197827A1 (en) * 1998-05-29 2009-08-06 Dunn Ben M Combination Therapy for Treatment of FIV Infection
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
EP2292190B1 (de) * 2000-10-16 2017-11-08 Conor Medsystems, Inc. Expandierbare medizinische Vorrichtung zur Freisetzung eines Heilmittels
JP4634694B2 (ja) * 2001-03-23 2011-02-16 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪アルコール薬物複合体
WO2002076402A2 (en) 2001-03-23 2002-10-03 Protarga, Inc. Fatty amine drug conjugates
EP2266590A3 (de) 2002-02-22 2011-04-20 Shire LLC Wirkstoff-Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Wirkstoffen
HUE043207T2 (hu) 2004-07-27 2019-08-28 Gilead Sciences Inc HIV-gátló vegyületek foszfonát analógjai
US20080269161A1 (en) * 2005-01-20 2008-10-30 Seth Perry Compositions and Methods Relating to Mitochondrial Hyperpolarization in Neurological Disease
EP1976976A4 (de) * 2005-12-23 2010-12-15 Univ Rochester Behandlung von neuro-aids unter verwendung von inhibitoren der glykogensynthase-kinase (gsk)-3
NZ572761A (en) * 2006-04-19 2011-09-30 Abbott Gmbh & Co Kg Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor
EP2364314B1 (de) 2008-12-09 2014-03-12 Gilead Sciences, Inc. Modulatoren von toll-like-rezeptoren
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
US9789012B2 (en) 2014-02-28 2017-10-17 Attends Healthcare Products, Inc. Absorbent article with multi-layer folded absorbent core
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
NZ728072A (en) 2014-07-11 2018-06-29 Gilead Sciences Inc Modulators of toll-like receptors for the treatment of hiv
EP3349757A1 (de) 2015-09-15 2018-07-25 Gilead Sciences, Inc. Modulatoren von toll-like-rezeptoren zur behandlung von hiv
EP3801424A1 (de) 2018-05-28 2021-04-14 Attends Healthcare Products, Inc. Trockenheitsschichtlaminat für absorbierende artikel

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
WO1994013629A1 (en) * 1992-12-11 1994-06-23 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease

Also Published As

Publication number Publication date
BR9611861A (pt) 1999-05-18
CA2238471A1 (en) 1997-06-12
DE69633680T2 (de) 2006-02-23
PL187747B1 (pl) 2004-09-30
NO317837B1 (no) 2004-12-20
US5646180A (en) 1997-07-08
NO982556L (no) 1998-06-04
ES2231828T3 (es) 2005-05-16
NO982556D0 (no) 1998-06-04
AU1148697A (en) 1997-06-27
CZ170898A3 (cs) 1998-09-16
JP2000501713A (ja) 2000-02-15
NZ324603A (en) 2000-08-25
RU2203658C2 (ru) 2003-05-10
PL327061A1 (en) 1998-11-23
EP0866696A1 (de) 1998-09-30
CN1203530A (zh) 1998-12-30
HUP9903673A3 (en) 2000-08-28
ATE279922T1 (de) 2004-11-15
AP9801340A0 (en) 1998-09-30
HUP9903673A2 (hu) 2000-03-28
PT866696E (pt) 2005-03-31
AP864A (en) 2000-08-11
KR19990071750A (ko) 1999-09-27
EP0866696B1 (de) 2004-10-20
OA10691A (en) 2001-05-04
AU722850B2 (en) 2000-08-10
CZ291994B6 (cs) 2003-07-16
UA61902C2 (en) 2003-12-15
WO1997020554A1 (en) 1997-06-12
ZA9610139B (en) 1997-06-17

Similar Documents

Publication Publication Date Title
DE69633680D1 (de) Behandlung von zns-wirkungen des hiv mit vx-478, allein oder kombiniert mit azt oder 3tc
TR199501053A2 (tr) Tedavide yararli spiro-azabisiklik bilesikler.
DE69104796D1 (de) Zusammensetzung für die Haarbehandlung.
BR9708360A (pt) Divisor de feixe não-polarizante e processo para produzir o mesmo
FR2701818B1 (fr) Applicateur.
DE69612279T2 (de) Behandlung schwerer aromaten
DK0811110T3 (da) Oliekildebehandling
DE69513916D1 (de) Oberflächenbehandlungszusammensetzung
DE69019973T2 (de) Wäschebehandlungszusammensetzung.
DE69106938T2 (de) Haarbehandlungsmittel.
ITRM930650A0 (it) Ornamento.
DE69622461T2 (de) Oberflächenbehandlungszusammensetzung
DE69022813D1 (de) Abfallbehandlung.
TR199500800A2 (tr) Sekil verilmis esyalarin üretilmesi.
BR9610382A (pt) Composição de tratamento do cableo
NL1000279C2 (nl) Met hitte behandelde polysacharidecrème.
IT1284920B1 (it) Trattamento del diamante
DE68908413D1 (de) Behandlung von metallbrammen.
NL1001157A1 (nl) Zuiveringsinstallatie.
TR199600041A2 (tr) Cilt temizleme bilesimi.
DE69517733D1 (de) Nachfüllen von Behandlungslösungen
DE69113570D1 (de) Behandlungsmittel.
ES1026557Y (es) Maquina peladora de ajos.
DE68921822T2 (de) Wäschebehandlungsmittel.
DE69100536D1 (de) Behandlung von abwasser.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee